Abstract
Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their lifetime, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary virulence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug resistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC research are also discussed in the context of future outlooks.
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence, Urinary Tract Infection, UPEC, UTI, bladder infection (cystitis), acute kidney infection (pyelonephritis), pathogens.
Current Drug Targets
Title:Uropathogenic Escherichia coli Mediated Urinary Tract Infection
Volume: 13 Issue: 11
Author(s): Makrina Totsika, Danilo Gomes Moriel, Adi Idris, Benjamin A. Rogers, Daniel J. Wurpel, Minh-Duy Phan, David L. Paterson and Mark A. Schembri
Affiliation:
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence, Urinary Tract Infection, UPEC, UTI, bladder infection (cystitis), acute kidney infection (pyelonephritis), pathogens.
Abstract: Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their lifetime, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary virulence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug resistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC research are also discussed in the context of future outlooks.
Export Options
About this article
Cite this article as:
Totsika Makrina, Gomes Moriel Danilo, Idris Adi, A. Rogers Benjamin, J. Wurpel Daniel, Phan Minh-Duy, L. Paterson David and A. Schembri Mark, Uropathogenic Escherichia coli Mediated Urinary Tract Infection, Current Drug Targets 2012; 13 (11) . https://dx.doi.org/10.2174/138945012803530206
DOI https://dx.doi.org/10.2174/138945012803530206 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Chronic Migraine with Intramuscular Pericranial Injections of Onabotulinumtoxin A
Recent Patents on CNS Drug Discovery (Discontinued) Infectious Causes of Childhood Disability
Infectious Disorders - Drug Targets Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Designing Promiscuous Drugs? Look at What Nature Made!
Letters in Drug Design & Discovery Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?
Current Medicinal Chemistry - Anti-Infective Agents A New Comprehensive Index for Evaluating the Quality of Infant Formula under the Framework of Chinese Food Standards
Current Bioinformatics Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Toll-Like Receptors: Sensor Molecules for Detecting Damage to the Nervous System
Current Protein & Peptide Science Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Directing the Antiretroviral Drugs to the Brain Reservoir: A Nanoformulation Approach for NeuroAIDS
Current Drug Metabolism The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neonatal Fever in the Term Infant: Evaluation and Management Strategies
Current Pediatric Reviews A Potential Andrographolide Analogue against the Replication of Herpes Simplex Virus Type 1 in Vero Cells
Medicinal Chemistry Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Ecological Infectomics (Ecoinfectomics): Symbiotic Solutions to Microbial Infections
Anti-Infective Agents Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis
Current Drug Targets Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Therapies for Neurological Disease in the Mucopolysaccharidoses
Current Gene Therapy